Cody Hiram S, Van Zee Kimberly J
Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA.
J Natl Compr Canc Netw. 2003 Apr;1(2):199-206. doi: 10.6004/jnccn.2003.0018.
Sentinel lymph node (SLN) biopsy, a new standard of care for staging invasive breast cancer, remains controversial for ductal carcinoma in situ (DCIS). Although DCIS has a natural history in which long-term distant disease-free survival (DDFS) is 98% to 99% and axillary node metastases are historically rare, three recent DCIS series have found SLN metastases in a surprising 6% to 13% of patients. The strongest argument for SLN biopsy in DCIS is the diagnostic uncertainty and inherent sampling error of conventional pathologic techniques. Definitive surgery (excision or mastectomy) reveals invasive cancer in 10% to 21% of patients with a preoperative core needle or surgical biopsy diagnosis of DCIS, all of whom become conventional candidates for SLN biopsy. In the absence of proven invasion, most positive SLN in DCIS are micrometastases detected by hematoxylin and eosin- and immunohistochemical-stained serial sections. An increasing body of evidence suggests that these are prognostically significant, not artifactual. We propose that DCIS patients with positive SLN have occult invasive cancers, and that the same may have been true for the 1% to 2% of DCIS patients who go on to develop distant metastasis, either after an invasive local recurrence or as a first event. We further suggest that the diagnosis of DCIS encompasses two patient populations: 1) a majority (perhaps 90%) with true in situ disease (or prognostically insignificant invasion), negative SLNs, and an expected DDFS of 100%; and 2) a minority (perhaps 10%) with occult invasion, positive SLNs, and an expected DDFS of perhaps 90%. Pending the development of predictive models for preoperative identification of this SLN-positive minority of DCIS patients, SLN biopsy is indicated in any DCIS patient who may have an underlying invasive cancer, especially those who require mastectomy. In DCIS, SLN biopsy may ultimately prove to be a more sensitive screening test for occult invasion than examination of the breast itself.
前哨淋巴结(SLN)活检是浸润性乳腺癌分期的一种新的标准治疗方法,但对于导管原位癌(DCIS)仍存在争议。尽管DCIS的自然病程中,长期远处无病生存率(DDFS)为98%至99%,且历史上腋窝淋巴结转移罕见,但最近的三个DCIS系列研究发现,令人惊讶的是,6%至13%的患者存在SLN转移。DCIS中进行SLN活检的最有力论据是传统病理技术的诊断不确定性和固有的抽样误差。确定性手术(切除或乳房切除术)在术前通过粗针穿刺或手术活检诊断为DCIS的患者中,有10%至21%发现浸润性癌,所有这些患者都成为SLN活检的常规候选者。在没有证实有浸润的情况下,DCIS中大多数SLN阳性为苏木精-伊红染色和免疫组化染色连续切片检测到的微转移。越来越多的证据表明,这些微转移具有预后意义,并非人为假象。我们提出,SLN阳性的DCIS患者存在隐匿性浸润性癌,对于1%至2%的DCIS患者,无论是在浸润性局部复发后还是作为首发事件发生远处转移,情况可能也是如此。我们进一步认为,DCIS的诊断包括两个患者群体:1)大多数(可能90%)为真正的原位疾病(或预后无意义的浸润)、SLN阴性且预期DDFS为100%;2)少数(可能10%)为隐匿性浸润、SLN阳性且预期DDFS可能为90%。在开发用于术前识别DCIS患者中这一SLN阳性少数群体的预测模型之前,对于任何可能存在潜在浸润性癌的DCIS患者,尤其是那些需要乳房切除术的患者,建议进行SLN活检。在DCIS中,SLN活检最终可能被证明是一种比乳房自身检查更敏感的隐匿性浸润筛查测试。